Scarica l'app Stockscreener
0.1015
5.14%
-0.0055
Dopo l'orario di chiusura:
.11
0.0085
+8.37%
Wellgistics Health Inc Borsa (WGRX) Ultime notizie
Wellgistics Health (WGRX) approves board-authorized 1:25–1:200 reverse split - Stock Titan
Wellgistics Health, Inc. (WGRX) Explores $105M Acquisition of Neuritek to Expand Healthcare Platform - insidermonkey.com
Wellgistics Health (WGRX) director Marlene Velez files Form 3 - Stock Titan
12 Penny Stocks with Insider Buying in 2026 - insidermonkey.com
Exclusive:Top Public Companies Holding XRP - Bitget
Sentiment Recap: How does Wellgistics Health Inc score in quality rankings2026 Trading Volume Trends & Technical Entry and Exit Tips - baoquankhu1.vn
Pullback Watch: Can Wellgistics Health Inc continue delivering strong returns2026 Bull vs Bear & Daily Growth Stock Tips - baoquankhu1.vn
[PRER14C] Wellgistics Health, Inc. Preliminary Revised Information Statement - Stock Titan
Thunder Rock Capital Serves as Exclusive M&A Advisor to Neuritek Therapeutics, Inc. on $105,000,000 Proposed Acquisition by Wellgistics Health, Inc. - ChartMill
Earnings Update: Does Wellgistics Health Inc align with a passive investing strategy2026 Setups & Accurate Technical Buy Alerts - baoquankhu1.vn
Why Are Shares Of Wellgistics Health Falling? - Sahm
Wellgistics Health (NASDAQ: WGRX) OKs flexible 1-for-25–200 reverse split - Stock Titan
WGRX Wellgistics Health (NASDAQ) earnings pre-market: $0.13 price, LOI in focus - Meyka
Wellgistics signs letter of intent to acquire Neuritek By Investing.com - Investing.com Australia
Wellgistics Health Inc. Evaluates $105M Acquisition of Neuritek Therapeutics - nationaltoday.com
Wellgistics Health shares are trading lower a... - Benzinga
Wellgistics signs letter of intent to acquire Neuritek - Investing.com
Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders - ACCESS Newswire
A pharmacy platform is weighing a $105M stock deal for a brain-drug developer - Stock Titan
Wellgistics Health 2025 10-K: $23.3M Revenue, $(1.43) EPS - TradingView
Wellgistics Health, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Wellgistics executives convert $2M debt to equity at premium By Investing.com - Investing.com India
Wellgistics executives convert $2M debt to equity at premium - Investing.com
Wellgistics Management Converts $2 Million in Deferred Compensation into Equity at $0.20 per Share - ACCESS Newswire
Wellgistics chief swaps $2M in deferred pay for locked-up stock - Stock Titan
Wellgistics Strengthens PharmacyChain(TM) with Insurance Eligibility & Benefits Verification Capabilities - ACCESS Newswire
Wellgistics Health Adds Quantum Key Encryption to PharmacyChain(TM) AI-Enabled Blockchain Smart Contract Partnership with DataVault AI - The Gardner News
Wellgistics shifts strategy to direct-to-consumer pharmacy model By Investing.com - Investing.com India
Wellgistics Health Inc. (WGRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Wellgistics shifts strategy to direct-to-consumer pharmacy model - Investing.com Australia
Is Wellgistics Health Inc stock good for income investors2026 Rallies & Expert Approved Momentum Ideas - baoquankhu1.vn
Wellgistics President Releases Letter to Shareholder on Emerging Patient Care-Centric Strategic Direction - ACCESS Newswire
This drug distributor plans to treat patients through an online pharmacy - Stock Titan
Wellgistics Integrates Insurance Eligibility & Benefits Verification Into PharmacyChain for Enhanced Healthcare Access and Cost Savings 1 - Minichart
Wellgistics Secures Preferred Pricing to Advance EBV Platform - TipRanks
Wellgistics Health, Inc. and KARE PharmTech, LLC Enter Interim Commercialization and Revenue Share Agreement - marketscreener.com
Health tech firm Wellgistics moves into $3B insurance check market - Stock Titan
Wellgistics Strengthens PharmacyChain(TM) with Insurance Eligibility & Benefits Verification Capabil - PharmiWeb.com
Wellgistics Launches Forzet Medical Food for GLP-1 Patients - The Globe and Mail
Wellgistics Launches Forzet™ to Address Muscle Loss in $70B GLP-1 Weight Loss Drug Market - Minichart
Wellgistics Health Reports Third Quarter 2025 Financial Results and Provides Business Update - The Gardner News
Wellgistics Launches Forzet(TM) to Address Muscle Loss from GLP-1 Drugs - National Today
Wellgistics Targets $70B Market Breakthrough Addressing Ozempic / GLP-1 Muscle Loss with Forzet(TM) - Asbury Park Press
Ozempic users face muscle loss; Forzet medical food targets it - Stock Titan
Wellgistics Health (NASDAQ: WGRX) launches Forzet medical food for GLP-1-related muscle loss - Stock Titan
1.13%
11.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):